Clinical experience with plerixafor as a mobilization regimen for autologous peripheral blood stem cell transplantation in patients with refractory germ cell tumors

García‑Escobar,Ignacio; Parrilla,Lucía; Ortega,Laura  Montejano; Castellanos,Daniel; Montalbán Pallarés,María   Ángeles; Cortés‑Funés,Hernán

doi:10.3892/mco.2014.362

Clinical experience with plerixafor as a mobilization regimen for autologous peripheral blood stem cell transplantation in patients with refractory germ cell tumors

Authors:
- Ignacio García‑Escobar
- Lucía Parrilla
- Laura Montejano Ortega
- Daniel Castellanos
- María Ángeles Montalbán Pallarés
- Hernán Cortés‑Funés
View Affiliations

Affiliations: Department of Medical Oncology, University Hospital 12 de Octubre, 28041 Madrid, Spain, Department of Hematology and Hemotherapy, University Hospital 12 de Octubre, 28041 Madrid, Spain
Published online on: July 29, 2014 https://doi.org/10.3892/mco.2014.362
Pages: 923-926

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of this study was to report our experience with administration of plerixafor for the mobilization of hematopoietic stem cells (HSCs) in patients with refractory or recurrent germ cell tumors who were candidates for salvage therapy with high‑dose chemotherapy and HSC transplantation and for whom mobilization of HSCs had not been achieved by standard therapies. This retrospective and observational study selected patients who were eligible for autologous HSC transplantation (AHSCT) and received plerixafor after failure of HSC mobilization by granulocyte colony‑stimulating factor (G‑CSF). A total of 5 patients (4 male and 1 female), aged 19‑41 years (mean age, 29.6 years) were initially selected. Four patients (80%) achieved an adequate HSC mobilization with plerixafor and subsequently received high‑dose chemotherapy followed by HSC transplantation. In these patients, the number of CD34+ cells collected following plerixafor mobilization was 1.8x106‑10.3x106 cells̸kg, with a peak CD34+ cell count of 7.0‑32.0 cells̸µl. Following HSC infusion, these 4 patients achieved a neutrophil count of >0.5x103̸mm3 and a platelet count of >20,000̸µl between days 10 and 14. Therefore, patients with high‑risk germ cell tumors eligible for AHSCT who are refractory to mobilization by G‑CSF, may benefit from the use of plerixafor, possibly to the same extent as patients with lymphoma and multiple myeloma.

View Figures

View References

1	Agarwala AK, Perkins SM, Abonour R, Brames MJ and Einhorn LH: Salvage chemotherapy with high-dose carboplatin and etoposide with peripheral blood stem cell transplant in patients with relapsed pure seminoma. Am J Clin Oncol. 34:286–288. 2011. View Article : Google Scholar : PubMed/NCBI
2	Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM and Abonour R: High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 357:340–348. 2007. View Article : Google Scholar : PubMed/NCBI
3	Kondagunta GV, Bacik J, Sheinfeld J, et al: Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol. 25:85–90. 2007. View Article : Google Scholar : PubMed/NCBI
4	Voss MH, Feldman DR and Motzer RJ: High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. Expert Rev Anticancer Ther. 11:1091–1103. 2011.PubMed/NCBI
5	Horwitz ME, Chute JP, Gasparetto C, et al: Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. Bone Marrow Transplant. 47:1051–1055. 2012. View Article : Google Scholar : PubMed/NCBI
6	Saure C, Weigelt C, Schroeder T, et al: Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer. Acta Haematol. 124:235–238. 2010. View Article : Google Scholar : PubMed/NCBI
7	Kobold S, Isernhagen J, Hübel K, et al: Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients. Bone Marrow Transplant. 46:1053–1056. 2011. View Article : Google Scholar : PubMed/NCBI
8	DiPersio JF, Micallef IN, Stiff PJ, et al: Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 27:4767–4773. 2009.PubMed/NCBI
9	DiPersio JF, Stadtmauer EA, Nademanee A, et al; 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 113:5720–5726. 2009.PubMed/NCBI
10	Maroto P, Garcí Del Muro X, Sastre J and Isla D: SEOM guidelines: non-seminomatous germ cell cancer (NSGCC). Clin Transl Oncol. 13:565–568. 2011. View Article : Google Scholar : PubMed/NCBI
11	Bokemeyer C, Harstrick A, Beyer J, et al: The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. Semin Oncol. 25:24–32; discussion 45–28. 1998.PubMed/NCBI
12	Lorch A, Mollevi C, Kramar A, et al: Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients. J Clin Oncol (ASCO Meeting Abstracts). 28:45132010.
13	Beyer J, Kingreen D, Krause M, et al: Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer. 79:161–168. 1997. View Article : Google Scholar : PubMed/NCBI
14	Tricot G, Cottler-Fox MH and Calandra G: Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant. 45:63–68. 2010. View Article : Google Scholar : PubMed/NCBI
15	Basak GW, Mikala G, Koristek Z, et al: Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it’s not too late. Leuk Lymphoma. 52:1711–1719. 2011.PubMed/NCBI
16	Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV and Stuart RK: Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant. 46:64–69. 2011. View Article : Google Scholar : PubMed/NCBI
17	Li J, Hamilton E, Vaughn L, et al: Effectiveness and cost analysis of ‘just-in-time’ salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion. 51:2175–2182. 2011.
18	Shaughnessy P, Islas-Ohlmayer M, Murphy J, et al: Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant. 17:729–736. 2011. View Article : Google Scholar : PubMed/NCBI